SVP of Intercept Pharmaceuticals just declared owning 11,592 shares of Intercept Pharmaceuticals

Lisa Defrancesco, SVP of Intercept Pharmaceuticals, has just filed an initial statement of beneficial ownership where 11,592 shares of Intercept Pharmaceuticals were declared. This form is usually filed as a prelude to receiving options or buying company shares, so there may be more to come from Defrancesco. Defrancesco operates out of New York, NY. Some additional info was provided as follows:


Includes both restricted stock units that represent a contingent right to receive one share of the Issuer's Common Stock, as well as shares of Common Stock.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48t h of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is October 1, 2019.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022

Auto Refresh

Feedback